Who can prescribe Wegovy? NP vs MD

Last Updated: December 17, 2025

If you’ve been considering medications like Wegovy, Ozempic, or Mounjaro for weight management, you’ve probably wondered: Can I get these prescriptions through telehealth? The short answer is yes—but the details depend on where you live and what your specific health needs are.

With the rise of telehealth services and the growing availability of GLP-1 medications for weight loss, more Americans than ever are accessing obesity treatment from the comfort of home. But navigating the patchwork of federal and state regulations can feel overwhelming. This guide breaks down everything you need to know about getting weight loss medication through telehealth in 2025.

Understanding the Basics: Federal Law and GLP-1 Medications

Here’s the good news: Federal law does not require an in-person visit before prescribing GLP-1 weight loss medications like Wegovy (semaglutide), Ozempic (semaglutide), or Mounjaro/Zepbound (tirzepatide).

These medications are not controlled substances, which means they’re exempt from the Ryan Haight Act’s in-person examination requirement that applies to drugs like Adderall or opioids. Since the COVID-19 pandemic accelerated telehealth adoption, the Drug Enforcement Administration (DEA) has maintained flexible policies for controlled medications—but GLP-1 drugs have always been eligible for telehealth prescribing under federal law.

What this means for you: A licensed healthcare provider can evaluate you via video consultation, determine if you’re a good candidate for treatment, and electronically send your prescription to a pharmacy—all without requiring you to visit an office in person.

The Current Regulatory Landscape

As of December 2025, the DEA’s COVID-era telehealth flexibilities for controlled substances remain in effect through December 31, 2025, with signals pointing toward another extension into 2026. However, because GLP-1 medications aren’t controlled substances, these temporary rules don’t affect your ability to access them via telehealth—this access has been and continues to be stable.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Differences: What You Need to Know

While federal law provides a foundation, individual states have their own requirements for telehealth prescribing. Some states require an initial in-person exam, while others allow the entire treatment process to occur virtually.

States That Allow Fully Virtual Treatment

Several states permit telehealth providers to prescribe GLP-1 medications without any in-person requirements:

California, Connecticut, Illinois, New York, Pennsylvania, and Washington are among the states with the most flexible telehealth policies. In these states, you can establish a patient-provider relationship through a live video consultation and receive your prescription entirely online.

For example, Washington has been a pioneer in telehealth access, with no in-person requirement and full independent practice authority for nurse practitioners. Similarly, New York allows telehealth exams to satisfy all prescribing requirements, with mandatory e-prescribing ensuring secure medication delivery.

States Requiring an Initial In-Person Visit

Other states maintain stricter standards, typically requiring at least one in-person examination:

Arkansas, Delaware, Georgia, Mississippi, New Jersey, North Dakota, South Carolina, Texas, Utah, and Virginia generally require an initial physical exam before a provider can prescribe weight loss medications via telehealth.

For instance, Texas requires healthcare providers to conduct an initial in-person evaluation before prescribing obesity medications through telehealth. This reflects the state’s conservative approach to telemedicine regulation, though follow-up visits can typically be conducted virtually.

New Jersey takes this a step further, requiring not just a physical exam but also comprehensive lab work, psychological screening, and a documented diet and exercise plan before prescribing any weight-loss medication.

States With Unique Requirements

Some states have additional stipulations that go beyond basic in-person requirements:

Florida mandates that patients receiving weight loss medications:

• Have a BMI of 30 or higher (or 27+ with weight-related health conditions)
• Be seen for follow-up visits at least once every three months during treatment
• Receive documented lifestyle counseling alongside medication

Virginia requires providers to:

• Conduct initial lab work and a physical examination
• Create a personalized diet and exercise plan
• Schedule a follow-up visit within 30 days of starting therapy
• Document informed consent specifically for weight-loss drug therapy

Connecticut requires behavioral counseling and a documented diet/exercise plan as part of any obesity treatment protocol.

Who Can Prescribe: Understanding Provider Qualifications

The type of healthcare provider who can prescribe your weight loss medication depends on state regulations governing nurse practitioners (NPs) and physician assistants (PAs).

States With Full NP Independence

In states with full practice authority, nurse practitioners can evaluate patients, diagnose conditions, and prescribe medications independently without physician oversight. As of December 2025, 34 states plus Washington, D.C. have granted NPs this level of autonomy.

States like California, New York, Washington, Arizona, Utah, and Virginia allow experienced NPs to practice independently. This often translates to greater telehealth availability, as NP-led services can operate more flexibly.

For example, California NPs who have completed at least three years of supervised practice can operate independently, making them key providers in telehealth weight loss programs.

States Requiring Physician Collaboration

Other states require NPs and PAs to work under physician supervision or collaboration agreements. These include Texas, Florida, Pennsylvania, Georgia, and Mississippi.

In Texas, NPs must have a formal prescriptive authority agreement with a supervising physician. While they can prescribe GLP-1 medications (which aren’t controlled), they cannot prescribe Schedule II controlled substances like stimulants—even with physician oversight.

Georgia recently expanded NP/PA authority in 2024, allowing them to prescribe Schedule II medications with physician delegation for the first time—a significant step forward for access.

Why This Matters for Telehealth

When you use a telehealth service, you might see an MD, DO, NP, or PA depending on availability and state regulations. Reputable platforms like Klarity Health ensure all providers are properly licensed and credentialed in your state, so you can feel confident about the legitimacy and quality of your care regardless of which type of provider you see.

Medical Eligibility: Who Qualifies for GLP-1 Weight Loss Medications?

Having access to telehealth doesn’t mean everyone qualifies for these medications. Providers must follow clinical guidelines to ensure patient safety.

Standard Clinical Criteria

Generally, you may be a candidate for GLP-1 weight loss medication if you meet these criteria:

BMI Requirements:

• BMI of 30 or higher (classified as obese), OR
• BMI of 27 or higher with at least one weight-related health condition (such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea)

Age: Most providers prescribe these medications only to adults (18+), though adolescent use is emerging in clinical practice under specialist care

Previous Weight Loss Attempts: You should have attempted lifestyle modifications (diet and exercise) without achieving adequate weight loss, unless medically inadvisable

Commitment to Lifestyle Changes: Medications work best when combined with nutrition counseling and increased physical activity

Medical Contraindications

Certain health conditions disqualify patients from GLP-1 therapy:

Absolute Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Current pregnancy or planning to become pregnant (must discontinue at least 2 months before conception)
• History of severe allergic reaction to semaglutide or tirzepatide

Relative Contraindications (requiring careful evaluation):

• History of pancreatitis
• Active gallbladder disease or history of gallstones
• Severe gastrointestinal disorders (gastroparesis, inflammatory bowel disease)
• History of suicidal ideation or severe depression (monitoring required)
• Diabetic retinopathy (requires close monitoring)

The Telehealth Evaluation Process

When you connect with a telehealth provider, expect a thorough evaluation that includes:

1. Comprehensive Medical History: Current medications, allergies, past medical conditions, surgical history
2. Weight History: Previous weight loss attempts, family history of obesity
3. Current Measurements: Height, weight, BMI calculation (often self-reported, though some services require photo verification)
4. Health Screening: Questions about contraindications, mental health status, reproductive plans
5. Lifestyle Assessment: Current diet, exercise habits, readiness for behavior change
6. Informed Consent: Detailed discussion of risks, benefits, alternatives, and realistic expectations

Legitimate telehealth providers will not guarantee you a prescription before completing this evaluation. If a service promises medication without asking detailed health questions, consider that a red flag.

How Telehealth Weight Loss Programs Work

Understanding the typical process can help you know what to expect when seeking treatment.

Initial Consultation

Most telehealth weight loss programs follow this general structure:

Step 1: Online RegistrationYou’ll complete a detailed health questionnaire covering your medical history, current medications, weight loss goals, and lifestyle factors. This typically takes 15-30 minutes.

Step 2: Live Video ConsultationYou’ll meet with a licensed provider (MD, DO, NP, or PA) via secure video call. This consultation usually lasts 20-45 minutes and includes:

• Review of your health history and current medications
• Discussion of weight loss goals and expectations
• Physical assessment (as much as can be done virtually—providers may ask you to demonstrate certain movements or show specific areas if relevant)
• Review of contraindications and risk factors
• Education about medication options, dosing, and side effects
• Development of a comprehensive treatment plan including lifestyle modifications

Step 3: Prescription and FulfillmentIf you’re a good candidate, your provider will electronically send your prescription to a pharmacy—either your preferred local pharmacy or a partner mail-order pharmacy. Initial prescriptions are often for 4 weeks to assess tolerance.

Ongoing Monitoring and Follow-Up

Responsible telehealth programs don’t just hand you a prescription and disappear. Quality care includes:

Regular Check-Ins:

• Week 2-4: Brief check-in (often via messaging or short call) to assess tolerance and side effects
• Month 1-2: Follow-up video visit to review weight loss, adjust dosing, and address any concerns
• Every 1-3 months thereafter: Ongoing monitoring visits

Lab Work:Some providers require periodic blood tests to monitor for potential complications:

• Baseline: Comprehensive metabolic panel, lipid panel, hemoglobin A1C, thyroid function
• Follow-up: Repeat labs every 3-6 months or as clinically indicated

Dose Titration:GLP-1 medications typically start at low doses and gradually increase to minimize side effects. Your provider will adjust your dose based on tolerance and weight loss response.

State-Specific Requirements:Remember that some states mandate specific follow-up schedules:

• Florida: At least one visit every 3 months
• Virginia: Check-in within 30 days of starting medication

What Klarity Health Offers

At Klarity Health, we make accessing evidence-based weight management care straightforward while maintaining the highest standards of medical practice. Our approach includes:

• Provider Availability: Licensed prescribers in multiple states, with availability that fits your schedule—often including evenings and weekends
• Transparent Pricing: Clear, upfront costs with no hidden fees. We accept both insurance and cash pay options to maximize accessibility
• Comprehensive Care: Not just prescriptions—our providers create personalized treatment plans that address nutrition, physical activity, and behavioral health alongside medication
• Flexible Follow-Up: Regular monitoring through the platform that works for your lifestyle, with responsive provider messaging between scheduled visits

Understanding Your Medication Options

Let’s break down the three most common GLP-1 medications prescribed for weight loss via telehealth:

Wegovy (Semaglutide 2.4 mg)

FDA Approval: Approved specifically for chronic weight management in adults with obesity or overweight with weight-related conditions

How It Works: Once-weekly injection that mimics GLP-1, a hormone that regulates appetite and blood sugar

Typical Results: Clinical trials showed average weight loss of 12-15% of body weight over 68 weeks when combined with lifestyle changes

Dosing: Starts at 0.25 mg weekly, gradually increasing to maintenance dose of 2.4 mg weekly over 16-20 weeks

Cost: Approximately $1,300-$1,500 per month without insurance; many insurance plans now cover it with prior authorization

Availability: Supply has stabilized as of 2025 after shortages in 2022-2023

Ozempic (Semaglutide 0.5-1 mg)

FDA Approval: Approved for type 2 diabetes; commonly prescribed off-label for weight loss

Key Difference from Wegovy: Lower maximum dose (1 mg vs. 2.4 mg) and packaged differently, but same active ingredient

Why It’s Prescribed: Some insurance plans cover Ozempic for weight loss when Wegovy isn’t covered, as it’s been on the market longer

Important Note: When prescribing off-label, providers must document their medical reasoning and obtain informed consent from patients. Reputable telehealth services will clearly explain that this is off-label use.

Mounjaro (Tirzepatide) / Zepbound

FDA Approval: Mounjaro approved for type 2 diabetes; Zepbound (same drug, different branding and dosing) approved for chronic weight management in late 2023

How It Works: Dual-action drug that mimics both GLP-1 and GIP hormones, potentially offering greater weight loss than semaglutide

Typical Results: Clinical trials showed average weight loss of 15-21% of body weight—among the highest for any obesity medication

Dosing: Starts at 2.5 mg weekly, increasing to maintenance doses of 5-15 mg weekly

Cost: Similar to Wegovy ($1,000-$1,400/month); insurance coverage expanding but still requires prior authorization in most cases

Availability: Generally good availability as of 2025

What About Compounded Versions?

Important Update: In May 2025, the FDA effectively banned routine compounding of semaglutide for weight loss after declaring the shortage over. This means:

• You should only receive FDA-approved, manufacturer-made versions of these medications
• Compounded versions are only allowed in very specific circumstances (such as documented allergies to inactive ingredients)
• Telehealth companies that previously offered cheaper compounded versions have largely discontinued these programs

Why this matters: While compounded versions were cheaper, they lacked FDA oversight for purity, potency, and sterility. The ban ensures you receive safe, effective medication with proper quality control.

Be wary of any telehealth service still promoting compounded semaglutide—this is a significant red flag for regulatory non-compliance.

Costs and Insurance Coverage

Understanding the financial aspect is crucial when considering telehealth weight loss treatment.

Medication Costs

Without Insurance:

• Wegovy: $1,300-$1,500/month
• Ozempic: $900-$1,000/month
• Mounjaro/Zepbound: $1,000-$1,400/month

With Insurance:Coverage varies widely. As of 2025:

• Medicare: Does not cover weight loss medications (federal law prohibition)
• Medicaid: Coverage varies by state; approximately 15 states provide some coverage
• Private Insurance: Increasingly covering these medications, but usually requiring:
• Prior authorization
• Documentation of BMI ≥30 (or ≥27 with comorbidities)
• Proof of previous weight loss attempts
• Ongoing lifestyle modification program

When covered, copays typically range from $25-$250/month depending on your plan.

Telehealth Service Fees

In addition to medication costs, telehealth programs charge for provider consultations:

Typical Fee Structures:

• Initial consultation: $50-$200
• Monthly follow-up visits: $30-$100
• Comprehensive programs: $99-$299/month (including consultations, messaging access, and care coordination)

What Klarity Health Offers:We provide transparent pricing with both insurance-based and cash-pay options. Our monthly plans include all provider consultations, unlimited messaging with your care team, and assistance with insurance prior authorizations—no surprise charges or hidden fees. We accept most major insurance plans and offer competitive self-pay rates for those without coverage or who prefer not to use insurance.

Savings Strategies

Manufacturer Savings Programs:

• Novo Nordisk offers savings cards for Wegovy and Ozempic (may reduce copays to as low as $25/month for eligible patients)
• Eli Lilly offers similar programs for Mounjaro/Zepbound

Appeal Denied Claims:If your insurance denies coverage, you have the right to appeal. Many telehealth providers (including Klarity) assist with this process by providing necessary documentation and letters of medical necessity.

Consider Tax Deductions:Medical expenses exceeding 7.5% of your adjusted gross income may be tax-deductible. Consult a tax professional about whether your weight loss treatment qualifies.

Red Flags: How to Identify Unsafe Telehealth Services

The popularity of GLP-1 medications has unfortunately attracted some disreputable operators. Protect yourself by watching for these warning signs:

Major Red Flags

🚩 Guaranteed PrescriptionsAny service that promises you’ll get a prescription without a thorough evaluation is cutting corners. Legitimate providers assess your medical suitability first—some patients may not be appropriate candidates.

🚩 No Live Provider ConsultationIf a service only requires filling out a form without a video or phone conversation with a licensed provider, it’s not meeting the legal standard for establishing a patient-provider relationship in most states.

🚩 Selling Compounded MedicationsAs of 2025, routine compounding of semaglutide is banned. Any service still offering ‘compounded Wegovy’ or overseas versions is operating outside FDA regulations and potentially putting your health at risk.

🚩 No Follow-Up CareResponsible weight management requires ongoing monitoring. If a service doesn’t include regular check-ins or makes follow-up visits difficult to access, look elsewhere.

🚩 Unclear LicensingThe provider prescribing your medication must be licensed in the state where you physically reside. If the service doesn’t clearly disclose provider credentials and state licenses, that’s a serious concern.

🚩 Too Good to Be True PricingIf medication costs seem impossibly low (e.g., $100/month for brand-name Wegovy), it’s likely either a scam, counterfeit medication, or an illegal compounded version.

🚩 No Discussion of RisksAny legitimate provider will thoroughly discuss potential side effects, contraindications, and alternative approaches. If a service glosses over risks or makes unrealistic promises about results, be skeptical.

What Quality Care Looks Like

In contrast, reputable telehealth weight loss services will:

✅ Require a comprehensive health questionnaire and live consultation✅ Clearly disclose provider credentials and state licenses✅ Discuss both benefits and risks of treatment✅ Offer alternatives and explain why medication may or may not be appropriate for you✅ Prescribe only FDA-approved, pharmacy-dispensed medications✅ Include structured follow-up care and monitoring✅ Have transparent pricing and billing✅ Provide clear contact information and responsive patient support✅ Assist with insurance verification and prior authorization when applicable

Common Questions About Telehealth Weight Loss Treatment

Can I get these medications if I don’t have obesity-related health problems?

Generally, yes—if your BMI is 30 or higher, you meet the criteria for obesity treatment regardless of whether you have additional conditions like diabetes or high blood pressure. However, if your BMI is 27-29.9, you’ll typically need to have at least one weight-related comorbidity to qualify.

How quickly will I lose weight?

Results vary significantly, but most people lose 1-2 pounds per week on average once they reach their therapeutic dose. Significant weight loss typically becomes apparent after 12-16 weeks. The medications work gradually—this isn’t a quick fix, and providers who promise rapid dramatic results are being misleading.

What are the most common side effects?

The most frequent side effects are gastrointestinal: nausea, diarrhea, constipation, vomiting, and abdominal discomfort. These are usually mild to moderate and improve as your body adjusts (typically within the first 4-8 weeks). Starting at a low dose and gradually increasing helps minimize these effects.

Can I switch between Wegovy, Ozempic, and Mounjaro?

You should never take more than one GLP-1 medication at a time. Switching between different GLP-1s is possible under provider supervision, though insurance may complicate this. Switching from a GLP-1 (like Wegovy) to tirzepatide (Mounjaro/Zepbound) may offer additional weight loss for some people, but requires careful transition.

What happens if I stop taking the medication?

Weight regain is common when these medications are discontinued. Studies show most people regain about two-thirds of lost weight within a year of stopping. These medications are intended for long-term use in managing chronic obesity, similar to how blood pressure or cholesterol medications are taken long-term.

Are these medications safe during pregnancy?

No. GLP-1 medications should be discontinued at least 2 months before trying to conceive. If you become pregnant while taking these medications, stop immediately and contact your healthcare provider.

Will my insurance cover telehealth consultations?

Most insurance plans now cover telehealth visits at the same rate as in-person visits, thanks to changes accelerated by COVID-19. However, coverage specifics vary by plan. Klarity Health can verify your insurance benefits before your first appointment.

The Future of Telehealth Weight Loss Treatment

The landscape of obesity care is evolving rapidly, and telehealth is positioned to play an increasingly important role.

Regulatory Trends to Watch

Federal Legislation: The TREATS Act, reintroduced in October 2025, aims to permanently expand telehealth prescribing authority for certain medications. While focused primarily on substance use disorder treatment, its passage would signal broader congressional support for telemedicine access.

State Modernization: Several states are considering legislation in 2026 to expand nurse practitioner independence and streamline telehealth requirements, potentially making access even easier.

DEA Extension: The temporary telehealth flexibilities for controlled substances (currently set to expire December 31, 2025) are expected to be extended again, reflecting the government’s recognition that telehealth access to prescription medications is here to stay.

Emerging Treatment Options

New Medications: Additional GLP-1 and dual-agonist medications are in late-stage clinical trials, potentially offering more options with different side effect profiles or administration methods (such as oral pills instead of injections).

Combination Therapies: Research is exploring combining GLP-1 medications with other weight loss approaches for enhanced results.

Personalized Medicine: Advances in understanding individual responses to these medications may lead to more personalized treatment selection based on genetic or metabolic factors.

Privacy Considerations

As telehealth expands, privacy protections are strengthening. States like Washington have enacted comprehensive health data privacy laws (the My Health My Data Act) that impose strict requirements on how telehealth companies handle sensitive information like weight, health conditions, and treatment details. Expect more states to follow suit, ultimately benefiting patients through stronger privacy safeguards.

Taking the Next Step

If you’re struggling with weight management and wondering whether GLP-1 medications might be right for you, telehealth offers a convenient, accessible way to explore your options with qualified healthcare providers.

Is Telehealth Weight Loss Treatment Right for You?

Consider telehealth if you:

• Have a BMI of 27 or higher
• Have tried diet and exercise without achieving sustainable weight loss
• Prefer the convenience of virtual consultations
• Live in an area with limited access to obesity medicine specialists
• Want to avoid the time commitment of frequent in-person visits

Telehealth may not be ideal if you:

• Have complex medical conditions requiring hands-on physical examination
• Live in a state requiring in-person visits and cannot accommodate this
• Prefer face-to-face interactions for medical care
• Have significant contraindications requiring specialist consultation

How Klarity Health Can Help

At Klarity Health, we’ve designed our weight management program to make evidence-based obesity treatment accessible while maintaining the highest standards of medical care:

🏥 Expert ProvidersOur licensed physicians, nurse practitioners, and physician assistants specialize in weight management and stay current with the latest research and guidelines.

⏰ Convenient AccessSchedule appointments that fit your life, with evening and weekend availability. No waiting rooms, no commute.

💰 Transparent PricingWe accept both insurance and offer competitive cash-pay rates. You’ll know exactly what you’re paying before your first visit—no surprise bills.

📱 Ongoing SupportBetween scheduled visits, message your provider with questions or concerns. We’re here to support your entire journey, not just hand you a prescription.

📋 Comprehensive CareOur approach goes beyond medication, incorporating nutrition guidance, activity recommendations, and behavioral strategies for long-term success.

Ready to get started? Visit Klarity Health to learn more about our weight management program and schedule your initial consultation. Take the first step toward sustainable weight loss with the convenience of telehealth and the expertise of dedicated healthcare providers.

References & Research Sources

Verified as of: December 17, 2025

Top 5 Key Citations:

1. DEA and HHS Official Announcement – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (November 15, 2024). U.S. Drug Enforcement Administration. Available at: www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. Axios Health News – ‘COVID-era telehealth prescribing extended for Adderall and other controlled substances’ (November 18, 2024). Available at: www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

3. McDermott Will & Emery Legal Analysis – ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025’ (November 18, 2024). Available at: www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025

4. Goodwin Procter Healthcare Alert – ‘The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (March 27, 2024). Available at: www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. Reuters Business News – ‘Hims & Hers to cut 4% of workforce amid ban on weight-loss drug copies’ (May 30, 2025). Available at: www.reuters.com/business/healthcare-pharmaceuticals/hims-cut-4-workforce-amid-ban-weight-loss-drug-copies-2025-05-30

Additional Sources:

• National Law Review – ‘Arkansas Telemedicine Regulation Updates’ (2024)
• Nextech Healthcare Blog – ‘Know Your State’s Laws Around Semaglutide’ (April 11, 2025)
• Texas Medical Board – Prescribing and Supervision Guidelines (Accessed December 2025)
• U.S. Senate Press Release – Murkowski, Whitehouse, Tillis, Warner – TREATS Act Reintroduction (October 28, 2025)
• Nurse Practitioner Online – ‘Nurse Practitioner Practice Authority Updates’ (December 4, 2025)
• Georgia Legislature – HB557 Prescriptive Authority Expansion (2023-2024)
• Mississippi Legislature – SB2672 Advanced Practice Registered Nurse Authority (2025)

Note: 15 of 18 sources used in research were published or updated in 2024-2025. All regulatory status information has been verified as current as of December 17, 2025. State telehealth laws are subject to change; readers should verify current requirements in their specific state before beginning treatment.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid